Evidence map›Paper›PMID 38950027›Full record

ArticlePloS one2024

Risk factors for toxoplasmosis in people living with HIV in the Asia-Pacific region.

Ki Hyun Lee, Awachana Jiamsakul, Sasisopin Kiertiburanakul, Rohidas Borse, Vohith Khol, Evy Yunihastuti, Iskandar Azwa, I Ketut Agus Somia, Romanee Chaiwarith, Thach Ngoc Pham and 14 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ki Hyun LeeDepartment of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul, South Korea.ORCID 0000-0002-3138-6685
Awachana JiamsakulThe Kirby Institute, UNSW Sydney, Kensington, New South Wales, Australia.
Sasisopin KiertiburanakulFaculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Rohidas BorseBJ Government Medical College and Sassoon General Hospital, Pune, India.
Vohith KholNational Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia.
Evy YunihastutiFaculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
Iskandar AzwaInfectious Diseases Unit, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
I Ketut Agus SomiaFaculty of Medicine, Udayana University - Prof. Dr. I.G.N.G. Ngoerah Hospital, Bali, Indonesia.
Romanee ChaiwarithDivision of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Thach Ngoc PhamNational Hospital for Tropical Diseases, Hanoi, Vietnam.
Suwimon KhusuwanChiangrai Prachanukroh Hospital, Chiang Rai, Thailand.ORCID 0000-0001-6975-057X
Cuong Duy DoBach Mai Hospital, Hanoi, Vietnam.
Nagalingeswaran KumarasamyCART CRS, Voluntary Health Services, Chennai, India.
Yasmin GaniHospital Sungai Buloh, Sungai Buloh, Malaysia.
Rossana DitangcoResearch Institute for Tropical Medicine, Muntinlupa City, Philippines.
Oon Tek NgNational Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.
Sanjay PujariInstitute of Infectious Diseases, Pune, India.
Man Po LeeQueen Elizabeth Hospital, Yau Ma Tei, Hong Kong SAR.
Anchalee AvihingsanonHIV-NAT/ Thai Red Cross AIDS Research Centre and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Hsin-Pai ChenTaipei Veterans General Hospital, Taipei, Taiwan.
Fujie ZhangBeijing Ditan Hospital, Capital Medical University, Beijing, China.
Junko TanumaNational Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-1697-7364
Jeremy RossTREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
Jun Yong ChoiDepartment of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul, South Korea.ORCID 0000-0002-2775-3315

Funding

The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
NIAID NIH HHS U01 AI069907
6 · The paper itself

Abstract

introductionToxoplasma gondii can cause symptomatic toxoplasmosis in immunodeficient hosts, including in people living with human immunodeficiency virus (PLWH), mainly because of the reactivation of latent infection. We assessed the prevalence of toxoplasmosis and its associated risk factors in PLWH in the Asia-Pacific region using data from the TREAT Asia Human Immunodeficiency Virus (HIV) Observational Database (TAHOD) of the International Epidemiology Databases to Evaluate AIDS (IeDEA) Asia-Pacific.

methodsThis study included both retrospective and prospective cases of toxoplasmosis reported between 1997 and 2020. A matched case-control method was employed, where PLWH diagnosed with toxoplasmosis (cases) were each matched to two PLWH without a toxoplasmosis diagnosis (controls) from the same site. Sites without toxoplasmosis were excluded. Risk factors for toxoplasmosis were analyzed using conditional logistic regression.

resultsA total of 269/9576 (2.8%) PLWH were diagnosed with toxoplasmosis in 19 TAHOD sites. Of these, 227 (84%) were reported retrospectively and 42 (16%) were prospective diagnoses after cohort enrollment. At the time of toxoplasmosis diagnosis, the median age was 33 years (interquartile range 28-38), and 80% participants were male, 75% were not on antiretroviral therapy (ART). Excluding 63 out of 269 people without CD4 values, 192 (93.2%) had CD4 ≤200 cells/μL and 162 (78.6%) had CD4 ≤100 cells/μL. By employing 538 matched controls, we found that factors associated with toxoplasmosis included abstaining from ART (odds ratio [OR] 3.62, 95% CI 1.81-7.24), in comparison to receiving nucleoside reverse transcriptase inhibitors plus non-nucleoside reverse transcriptase inhibitors, HIV exposure through injection drug use (OR 2.27, 95% CI 1.15-4.47) as opposed to engaging in heterosexual intercourse and testing positive for hepatitis B virus surface antigen (OR 3.19, 95% CI 1.41-7.21). Toxoplasmosis was less likely with increasing CD4 counts (51-100 cells/μL: OR 0.41, 95% CI 0.18-0.96; 101-200 cells/μL: OR 0.14, 95% CI 0.06-0.34; >200 cells/μL: OR 0.02, 95% CI 0.01-0.06), when compared to CD4 ≤50 cells/μL. Moreover, the use of prophylactic cotrimoxazole was not associated with toxoplasmosis.

conclusionsSymptomatic toxoplasmosis is rare but still occurs in PLWH in the Asia-Pacific region, especially in the context of delayed diagnosis, causing advanced HIV disease. Immune reconstitution through early diagnosis and ART administration remains a priority in Asian PLWH.

Indexed as

HIV InfectionsToxoplasmosisAdultAsiaCase-Control StudiesFemaleHumansMaleMiddle AgedPrevalenceProspective StudiesRetrospective StudiesRisk FactorsToxoplasma

Identifiers

PMID38950027
PMCPMC11216616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.